Biotech | May 16, 2022
Inmagene receives USFDA IND clearance for a third-generation BTK inhibitor
It is developing the drug candidate to potentially treat immunological diseases
It is developing the drug candidate to potentially treat immunological diseases
In clinical trials, treatment proved more effective than other therapies evaluated
The mRNA vaccine candidate is fully indigenous and devoid of any technology contributions from elsewhere
CEPI will provide funding of up to US $19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
It includes multiple studies demonstrating that post-translational modifications of conformational variants of p53 are associated with the pathogenesis of Alzheimer's Disease
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Terran to advance the development of two of Sanofi's Phase 3 CNS therapeutics
Approval for primary and booster immunization is based on efficacy and safety data from Japan and international clinical studies
The report pointed out that in the process of treating Covid-19, there are promising data to suggest that TCM is beneficial in reducing the risk of progression from mild-to-moderate cases to severe Covid-19
Subscribe To Our Newsletter & Stay Updated
